Three absurdly cheap dividend stocks that are trading at modest multiples of their expected earnings today are Merck (NYSE: ...

The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.

With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give ...

FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.

The Ministry of Health and Welfare announced that health insurance for Paxlovid Jung of Pfizer Pharmaceutical Korea and Veclurizu of Gilead Sciences Korea ...

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00. The ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,150.00.

It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

The Biden administration on Oct. 21 issued a new proposed rule that would require health insurance providers to cover an ...

Privately held Dyno Therapeutics Inc. has added another notch to its adeno-associated virus (AAV) vectors development ...